Bayer magazine
Story

China – the new economic miracle

Sound off
  • Illuminating: Since the beginning of 2011, a large Bayer Cross has once again graced the skyline of Shanghai. It shines from a high-rise building in the business district of Xu Hui.
  • Testing: At the research facilities in Beijing, Bayer HealthCare employee Jin Weihua studies the dissolution behavior of the antihypertensive drug Adalat.
  • Evaluating: At the Global Footwear Competence Center in Shanghai, Erika Zhu (right) and Xiang Liu from Bayer MaterialScience inspect freshly cast shoe soles.
  • Counselling: In a rice paddy field in the southern Chinese ­province of Guangxi, Bayer CropScience expert Tan Kunzu explains to farmer Liang Mao Lan the advantages of targeted treatment with crop protection products.
  • Shanghai: At the Bayer MaterialScience site, employees like Gary Xi produce raw materials for polyurethanes and polycarbonates. The photo shows Xi inspecting the polycarbonates plant.
  • AN ACTIVE START: Residents of Shanghai do tai chi exercises against the city’s morning skyline.
ECONOMIC BOOM: With double-digit growth rates, ­capital expenditures worth billions and annual sales ­currently totaling €2.9 billion, China has become one of the most important single markets for the Bayer Group. The result is a partnership characterized by expertise, continuity and mutual respect.
Economic miracle – it’s a familiar term. Rapid rebuilding under unfavorable circumstances, challenges as far as the eye can see, and the courage to improvise. And a clear, overriding goal: tomorrow things will be better – and we are firmly convinced we’ll make it.
China today is a nation on the ascent, driven by a collective desire for prosperity and international recognition; a society of 1.3 billion people that is on track to become the world’s leading economic power.
Greater China is becoming increasingly important for Bayer. The result is a partnership characterized by expertise, continuity and mutual respect.
China took first place in the most recent PISA study in the area of mathematics, produces 6.3 million college graduates each year and now has 420 million Internet users. “The era of China as a producer of cheap goods is coming to an end – the country is quickly developing into a high-tech nation,” says Dr. Wolfgang Plischke, who is responsible on the Bayer Group Management Board for the Asia/Pacific region, describing the fundamental transformation China is undergoing. A systematic reform policy was not introduced until 1978 under Deng Xiaoping. Two years later, the first special economic zones were created and joint ventures were formed with companies in the west. In 1992 the government decided to move away from the conventional planned economy, and at the beginning of the new millennium China joined the World Trade Organization. The country began to host international events with increasing self-confidence: in 2004 a Formula 1 racing grand prix was brought to Shanghai, in 2008 the summer Olympic Games were staged in Beijing in impressive fashion, and two years later Shanghai hosted the World Expo 2010.

Economic boom

China has emerged from the most recent financial and economic crisis in an even stronger position. Economists agree that within just a few years, China will surpass the United States, as it has already done with Japan, to become the world’s leading economic power. The government’s rapidly implemented stimulus package consists primarily of infrastructure improvements, and is having a positive impact on the construction industry and other sectors. China currently boasts 193 cities with more than one million inhabitants, as well as half of all global construction activities.
Bayer aims to expand its capacities in China
The country’s economic boom is raising the quality of life – yet not as quickly and equitably as many people would like. The government is focusing all the more closely on maintaining stability and ensuring that citizens benefit from as much of the new affluence as possible. High on the list of priorities are health care and nutrition. It is planned for each Chinese citizen to have access to affordable basic medical care by 2020. Between 2009 and 2011 alone, this area will be the focus of nearly €10 billion in investment. One of numerous measures being undertaken within this timeframe is the planned doubling of the number of hospitals in the country to 40,000. When it comes to important targets, ‘planned’ in China means it’s as good as a done deal.
Harvest shortfalls led to periods of famine among broad sections of the Chinese population until the 1960s. According to the Food and Agriculture Organization of the United Nations, China today feeds more than one fifth of the world’s population with only ­seven percent of the global planting ­area. Additional challenges are posed by the shifting of the population base from rural areas to cities. Quality expectations are rising, eating habits are changing and meat consumption is increasing. Here, too, the government is introducing reforms and striving for supply security, quality and efficiency. The result is that agriculture is becoming a science.
The size of the country, which is comparable to that of the United States or Canada, requires particular efforts in the area of mobility. According to government statistics, eight new civilian airports opened in 2010 alone, in addition to the 166 existing ones. By the end of 2020 the government is aiming for a total of 244 airports to be in operation. China already has the most extensive high-speed rail network in the world, at 8,300 kilometers – but this is nowhere near enough. A further 17,000 kilometers are currently under construction, with nearly 5,000 expected to be completed this year.
The figures for China’s auto industry are also impressive. While nearly three million new cars were registered in Germany in 2010, some 18 million vehicles were sold in China according to the manufacturers’ association – 32 percent more than in the previous year. China now has the world’s biggest automotive market – yet at 50 cars per 1,000 citizens, it is still at the level of the United States in 1917.
China’s breathtaking economic development is being driven by three core needs: universal health care coverage, safe and healthy food for all and technological solutions for a smoothly functioning infrastructure. “Our core competencies are practically tailor-made for China’s needs,” says Management Board member Plischke. So it is no wonder that Bayer has a lot to offer China. The company has been represented in China for more than 125 years, and is therefore known and ­respected among customers as a ­dependable partner. In addition to ­Bayer’s reliability, it is above all the company’s innovative capability that makes Bayer such a valuable partner. This applies particularly to the Bayer Health­Care subgroup, whose portfolio ranges from antibiotics such as Ciprobay and Avalox through cardiovascular drugs like Adalat and the market-leading diabetes medicine ­Glucobay to Aspirin. Sales of the HealthCare subgroup now lie just below the magic €1 billion threshold, compared with €150 million in 2005.

Investment in research

The workforce has since grown to around 5,000 employees, and the company is intensifying its activities especially in the sales force and research. It is also planned to add a further 1,000 employees – for example to strengthen the sales team and better exploit business in rural areas. “Patients in China are different from those in western Europe in a number of ways,” stresses Chris Lee, Head of Bayer HealthCare in China. “We are systematically adjusting to these differ­ences.” The company wants to considerably strengthen its innovation capability in the future with a new research center in Beijing. Bayer will invest €100 million in the build-up of these activities over a five-year period in order to be able to work more closely with local experts. Similar collaborations with local partners are crucial to Bayer’s success in the area of agriculture as well. “A top priority is to optimize cultivation methods and thus increase crop quality and yields,” emphasizes Frank Dietrich, Head of Bayer CropScience in China. “At the same time, we are supporting farmers with our expertise through our Food Chain Program – from seed through cultivation to selling.” Alongside modern crop protection products, high-quality seed also ensures healthy plants and high-yield harvests. Here Bayer is also working closely with governmental agencies and institutes of higher learning to promote food production while protecting the environment. With 560 employees and annual sales of around €130 million in 2010, Bayer CropScience is now the second-biggest crop protection company in China.
The “Chinese economic miracle” is also buoying the business of Bayer ­MaterialScience, which employs 2,200 people in the country. The subgroup’s products provide the building blocks for innovative solutions, whether for the construction or automotive industries, for manufacturers of consumer electronics or furniture. Few countries put as much effort as China into promoting the development of new technologies in the area of energy efficiency – technologies that also benefit environmental protection.
Increase: The illustration shows Bayer Group sales in Greater China growing from €2.1 billion in 2009 to an estimated €6 billion in 2015.Zoom image
Increase: The illustration shows Bayer Group sales in Greater China growing from €2.1 billion in 2009 to an estimated €6 billion in 2015.
Overall the company aims to increase its sales in Greater China to around €6 billion by 2015. The plan is for Material­Science to contribute around half of this total. “Bayer’s success story is based on billions in early investments at the integrated site near Shanghai,” explains Management Board member Plischke. Thanks in part to Bayer Technology Services and its roughly 560 employees in China, the site quickly developed into a production hub for the region – and further rapid expansion is now planned through new investment. According to Plischke, Bayer will more than double its capacities for polyurethane raw materials and polycarbonate within a very short period of time, expand its coating raw materials production and considerably strengthen its ­local research and development capacities. “Through 2016 we will invest a further €1 billion in this strategically important site,” says Plischke, illustrating the magnitude of the current expansion program. At the beginning of the year, furthermore, the Polycarbonates business unit transferred its headquarters from Leverkusen to Shanghai.
In China as well, partnership is the key to our regional success. Bayer maintains research collaborations in the country and finances professorships in areas such as intellectual property rights and sustainable industrial development. An issue of particular importance is the health care system. Bayer promotes understanding among journalists of diseases and their transmission, and supports the health ministry in training medical specialists in rural areas.
Bayer is well known in China, and valued as an innovative, global company with German roots. The company’s employees there are mainly of Chinese nationality, and the average age is relatively young at 31. “Under the Bayer Cross the team combines German virtues with some typically Chinese characteristics. Among these traits are attentive listening and quick action, a self-confident approach to major challenges and an optimistic attitude,” says Cathy Gui, Head of Human Resources at Bayer China. Above all, however, there is one characteristic that Bayer’s many employees around the world share: a passion for joint success.
http://www.bayer.com/en/china-the-new-economic-miracle.aspx

Copyright © Bayer AG

Special Interest

Print page

Search
Bayer magazine

Contact adresses

Bayer China Ltd.
No 33, Huayuan Shiqiao Road
Shanghai 200120
Pudong 18-19/F, 23-26/F, Citigroup Tower
China
phone: +86-21-63618282
fax: +86-21-63606589
http://www.bayer.com.cn/
Last updated: March 7, 2012

×